Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OROS hydromorphone · 2 trials · 3 indications
The analgesic effect was assessed by the BPI item 5 "pain on average" using a 0 to 10 numeric rating scale, with 0 being "no pain" and 10 being "pain as bad as you can imagine".
Assessment of non-inferiority of OROS hydromorphone compared with sustained release (SR) oxycodone with regard to pain control by measuring the change from baseline in pain severity, using BPI item 6 "pain right now" score at week 24. Scores could have ranged from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. Negative change from baseline scores indicate improvement in "pain right now".
Assessment of non-inferiority of OROS hydromorphone compared with SR oxycodone with regard to pain control by measuring the change from baseline in pain severity, using BPI item 6 "pain right now" score at week 24. Scores could have ranged from 0 to 10, where 0 = no pain and 10 = pain as bad as you can imagine. Negative change from baseline scores indicate improvement in "pain right now".
If non-inferiority of OROS hydromorphone was established, the daily dose of OROS hydromorphone and SR oxycodone that induced the same pain control was to be calculated (average dose used at week 24). Relative equi-analgesic dose was defined as mean dose/allowed maximum dose\*100. Allowed maximum doses were 32mg OROS hydromorphone and 80mg SR oxycodone respectively.
If non-inferiority of OROS hydromorphone was established, the daily dose of OROS hydromorphone and SR oxycodone that induced the same pain control was to be calculated (average dose used at week 24). Relative equi-analgesic dose was defined as mean dose/allowed maximum dose\*100. Allowed maximum doses were 32mg OROS hydromorphone and 80mg SR oxycodone respectively.
Dose of OROS hydromorphone and SR oxycodone that induced the same pain control at steady state, defined as the mean dose from week 4 to week 24.
Dose of OROS hydromorphone and SR oxycodone that induced the same pain control at steady state, defined as the mean dose from week 4 to week 24.
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks |
| 002 | PLACEBO_COMPARATOR | Placebo placebo tablet once daily for 16 weeks |
| Oxycodone | ACTIVE_COMPARATOR | - |
| OROS hydromorphone HCl | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| OROS hydromorphone HCl | DRUG | 4 to 32 mg taken orally once daily for 16 weeks |
| Placebo | DRUG | placebo tablet once daily for 16 weeks |
| Oxycodone | DRUG | 10, 20, or 40 mg twice a day for 52 weeks (flexible dosing) |
Inclusion Criteria: * Documented Osteoarthritis of the hip or knee * Chronic pain for more than 3 months treated with daily analgesic for the last month * Moderate to severe OA pain of the target joint, which cannot be adequately treated with non-steroidal anti-inflamatory drugs or paracetamol * Mo...
OROS hydromorphone is an investigational small molecule being developed for pain, including chronic noncancer pain and moderate to severe pain caused by osteoarthritis of the hip or knee. It is a sustained-release formulation of hydromorphone, a strong opioid, and is currently in Phase 3 clinical development.
OROS hydromorphone is being developed by Johnson & Johnson, traded on the New York Stock Exchange under the ticker JNJ. The company is conducting Phase 3 clinical trials to evaluate the drug's effectiveness and safety in patients with pain.
OROS hydromorphone is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total enrollment of 792 patients, but the drug remains under investigation.
OROS hydromorphone has been studied in two completed Phase 3 trials. NCT00261495 enrolled 504 patients with chronic noncancer pain across multiple European countries. NCT00980798 enrolled 288 patients with moderate to severe osteoarthritis pain of the hip or knee in Czechia, Romania, Slovakia, and the United Kingdom.
OROS hydromorphone is a sustained-release formulation of hydromorphone, a strong opioid analgesic. It works by binding to opioid receptors in the central nervous system to relieve pain. The OROS delivery system provides controlled release of the medication over an extended period.